Skip to Content
Merck
All Photos(2)

Key Documents

HCMBMAG-22K

Millipore

MILLIPLEX® Human Cancer/ Metastasis Biomarker Magnetic Bead Panel - Cancer Multiplex Assay

Circulating Cancer and Metastasis Biomarker Bead-Based Multiplex Assays using the Luminex technology enables the simultaneous analysis of multiple oncology biomarkers in various tumor types in human serum, plasma and cell culture samples.

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Quality Level

species reactivity

human

manufacturer/tradename

Milliplex®

assay range

accuracy: 70-105%
standard curve range: 0,019-80 ng/mL
(TRAP5)

standard curve range: 0,048-20 ng/mL
(YKL40)

standard curve range: 0.002-10 ng/mL
(GDF15)

standard curve range: 0.007-30 ng/mL
(DKK-1)

standard curve range: 0.007-30 ng/mL
(OPG)

standard curve range: 0.036-150 ng/mL
(NSE)

standard curve range: 0.195-800 ng/mL
(Periostin)

standard curve range: 0.976-4,00 0 ng/mL
(Osteonectin (SPARC))

inter-assay cv: <16%
intra-assay cv: <10%

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

General description

The MILLIPLEX®Human Cancer/Metastasis Biomarker Panel 1 contains nine metastasis biomarkers that have also been identified in a variety of tumor types. Coupled with the Luminex® xMAP® platform in bead format, this panel enables researchers to focus on discovery with the advantage of simultaneous quantitative multiplex detection leading to speed and sensitivity.

Metastasis is a complex process in which tumor cells leave the primary tumor site and migrate to other parts of the body via blood and lymph vessels or by tumor invasion of surrounding tissues and organs. Breaking away from the primary tumor, cancer cells attach to and degrade extracellular matrix proteins that separate tumor from surrounding tissues to escape into the stroma. Where metastases form often depends on the primary tumor. Bone metastases, for example, tend to arise from breast, prostate and kidney tumors. This organ/tissue specificity seems to involve chemical signals from both chemokines and growth factors.

Panel Type: Circulating Cancer

Application

  • Analytes: DKK-1, GDF-15, Neuron-specific Enolase (NSE), Osteonectin (SPARC), Osteoprotegerin (OPG), Periostin, TRAP5, TWEAK, YKL40 (CHI3L1)
  • Recommended Sample Type: Human serum, plasma, and tissue/cell culture supernatants or lysates
  • Recommended Sample Dilution: 25 μL of 1:10 diluted serum or plasma; tissue/cell culture supernatants or lysates diluted may be diluted as needed in appropriate control medium
  • Assay Run Time: Overnight (16-18 hours) at 2-8°C
  • Research Category: Cancer

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

Other Notes

Sensitivity: Refer to kit protocol for sensitivities of individual biomarkers.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Target Organs

Respiratory Tract

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R H Brophy et al.
Osteoarthritis and cartilage, 27(12), 1778-1789 (2019-08-21)
Emerging evidence suggests that injury to the anterior cruciate ligament (ACL) typically initiates biological changes that contribute to the development of osteoarthritis (OA). The molecular biomarkers or mediators of these biological events remain unknown. The goal of this exploratory study
Paul G Corn et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(5), 990-999 (2020-01-17)
Cabozantinib, an oral inhibitor of c-MET/VEGFR2 signaling, improved progression-free survival (mPFS) but not overall survival (OS) in metastatic castrate-resistant prostate cancer. We evaluated cabozantinib plus androgen deprivation therapy (ADT) in hormone-naïve metastatic prostate cancer (HNMPCa). Patients received ADT plus cabozantinib
Alison Crichton et al.
Journal of neurotrauma, 38(8), 1151-1163 (2019-12-28)
Despite many children experiencing fatigue after childhood brain injury, little is known about the predictors of this complaint. To date, traditional indices of traumatic brain injury (TBI) severity have not predicted reliably persisting fatigue (up to three years post-injury). This

Related Content

Cancer biomarker detection through MILLIPLEX® multiplex cancer assays can accelerate studies of tumorigenic processes helping advance cancer research.

Cancer biomarker detection through MILLIPLEX® multiplex cancer assays can accelerate studies of tumorigenic processes helping advance cancer research.

Cancer biomarker detection through MILLIPLEX® multiplex cancer assays can accelerate studies of tumorigenic processes helping advance cancer research.

Cancer biomarker detection through MILLIPLEX® multiplex cancer assays can accelerate studies of tumorigenic processes helping advance cancer research.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service